We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > ARQ 531

News List

How Merck's desire for more 'control' became a $2.7B ArQule buy fiercepharma
December 20, 2019
It’s not uncommon for partnership talks focused on one drug to escalate into a full-on buyout. And that's just what happened with Merck & Co.’s $2.7 billion deal for ArQule.
Merck to Acquire ArQule americanpharmaceuticalreview
December 12, 2019
Merck and ArQule announced the companies have entered into a definitive agreement under which Merck, through a subsidiary ...
Merck to acquire ArQule in $2.7bn deal pharmaceutical-technology
December 11, 2019
Merck (MSD) has signed a definitive agreement to acquire biopharmaceutical company ArQule for a total cash consideration of $2.7bn, or $20 per share.